OncoSec Medical Stock

OncoSec Medical FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of OncoSec Medical (ONCS) as of Aug 13, 2026 is 94.74 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 94.30 % — a change of 0.47% (higher).

FCF Conversion

94.74 %

YoY

0.47%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of OncoSec Medical is 2026 94.74 % . FCF Conversion Rate (FCF/EBITDA) of OncoSec Medical was 2025 94.30 % . It decreases by 0.47% higher compared to the previous year.
Access this data via the Eulerpool API

OncoSec Medical Stock analysis

What does OncoSec Medical do? OncoSec Medical Inc is a US-based company specializing in the development of cancer treatment methods through immunotherapy. The company was founded in 2011 and is headquartered in San Diego, California. The history of OncoSec Medical Inc began with the idea of improving tumor treatments through electroporation. Electroporation is a process that uses electric pulses to increase the permeability of cell membranes. This facilitates the exchange of molecules and the uptake of drugs, which is used in the treatment of cancer cells. The business model of OncoSec Medical Inc is based on the development and commercialization of immunotherapies to combat cancer. Electroporation is used to locally infect tumor lesions with reactivated T-cells and other immune cells to generate an immune response. OncoSec Medical Inc has developed a proprietary platform called ImmunoPulse, which combines electroporation and immunotherapy. The company is divided into various divisions, including research and development, clinical trials, manufacturing, and distribution. Research and development focus on identifying potential immunotherapies and testing drug candidates. Clinical trials are designed to confirm the effectiveness and safety of therapies through clinical testing. Manufacturing involves the production of drug candidates and clinical preparations in accordance with Good Manufacturing Practices (GMPs). Distribution includes the sale and marketing of approved therapies to patients and healthcare providers. OncoSec Medical Inc offers a variety of immunotherapies for the treatment of various types of cancer. This includes ImmunoPulse IL-12 therapy, which is used to treat metastatic melanoma. The company is also working on several other therapies, including the Verapamil-Plus-IL-2 protocol for the treatment of breast and prostate cancer. In summary, OncoSec Medical Inc is an emerging biotechnology company specializing in the development and commercialization of immunotherapies to combat cancer. Through its proprietary ImmunoPulse platform and extensive research and development, the company strives to provide effective and safe treatment options for cancer patients, fully harnessing the potential of immunotherapy. OncoSec Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OncoSec Medical stock

FCF Conversion Rate (FCF/EBITDA) of OncoSec Medical is 94.74 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of OncoSec Medical changed from 94.30 % to 94.74 %, representing a 0.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) OncoSec Medical since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s OncoSec Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — OncoSec Medical

All Key Metrics — OncoSec Medical